KalVista製藥 KALV 深 滬
等待開盤 08-21 09:30:00 美东时间
27.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 27.00
- 總市值 14.38亿
- 52周最高 27.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9.83
- 委 比 0.00%
- 總股本 5324.09万
- 歷史最高 45.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.12
- 每 手 1
- 風險率 4.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced second quarter 2026 financial results and updates on ALXN1840 for Wilson Disease. The company initiated a rolling NDA submission for ALXN1840, received Rare Pediatric Disease (RPD) designation, and presented positive Phase 3 and Phase 2 clinical data. Financially, the company reported a net loss of $5.3 million and increased R&D and G&A expenses. Cash reserves of $134.3 million are expected to support operations thr...
08-12 13:30
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
Mobia Medical, Inc. has appointed Reza Zadno, Ph.D., as an independent director and member of the Compensation Committee. Dr. Zadno, with over 35 years of medical technology experience, has a track record of leading companies through IPOs and commercial expansion. He currently serves as an Operating Partner at Jolt Capital and a Special Advisor to the American Academy of Ophthalmology. Mobia Medical specializes in stroke recovery solutions, inclu...
07-15 20:05
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
New On The Block Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced that, after extensive consideration of the company's pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternative...
06-13 02:40
KalVista新数据揭示注射治疗给幼儿HAE患者带来沉重负担
KalVista Pharmaceuticals周四在2026年国际药物经济学与结果研究学会年会及东部过敏会议上公布的新数据显示，针对2至11岁遗传性血管性...
05-28 23:16
KalVista Pharmaceuticals Announces New Data That Highlight Burden Of Injectable On-Demand Treatment In Children Aged 2–11 With Hereditary Angioedema
"These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them," said Ben Palleiko, Chief Executive Officer of KalVista. "Currently, the only FDA-approved
05-28 19:12
Full Transcript: DRI HEALTHCARE TRUST Q1 2026 Earnings Call
DRI HEALTHCARE TRUST (TSX:DHT) held its first-quarter earnings conference call ...
05-15 21:47
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-15 05:22
5月医疗保健股多空榜：Sensei及KalVista空头比例居前
随着4月结束，市值20亿美元以下的小型医疗保健股空头头寸显著增加，显示市场对这类高波动性股票的看空情绪升温。 根据最新数据，5月初医疗保健板块空头比例最...
05-05 03:24
美股周涨跌榜 | 净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%
累计净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%，Q1营收同比翻倍大超预期>>
05-04 18:33
